Exploration of effective dose and safety of phosphopropofol disodium in the anesthetized patients undergoing gastroenteroscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060626

Enrollment

Unknown

Registered

2022-06-06

Start date

2022-05-31

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive disease

Interventions

Group 1:Fospropofol 6.4 mg/kg

Group 2:Fospropofol 8.0 mg/kg

Group 3:Fospropofol 10.0 mg/kg

Group 4:Fospropofol 12.5 mg/kg

Group 5:Fospropofol 15.6 mg/kg

Group 6:Fospropofol 19.5 mg/kg

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients undergoing gastroenteroscopy in digestive endoscopy room; (2) Patients aged 20-75, with no gender limitation; (3) The body weight of the patient was 45kg-85kg, and the development was normal; (4) ASA grade of patients was ?- ?. (5) The patient has normal thinking and smooth language communication.

Exclusion criteria

Exclusion criteria: (1) Patients complicated with cardiopulmonary and cerebral diseases; (2) Patients with liver or kidney insufficiency; (3) Patients with anemia or coagulation disorder; (4) The patient's history of food or drug allergy; (5) Recent use of psychotropic drugs; (6) The patient's mental state is highly stressed; (7) The patient has long-term bad habits such as smoking or drinking.

Design outcomes

Primary

Measure	Time frame
Onset time;Duration of procedure;Recovery time;total dose;	—

Secondary

Measure	Time frame
Drug-related adverse reactions;	—

Countries

China

Contacts

Public ContactXin Jin

First Affiliated Hospital of Soochow University

jinxin@suda.edu.cn+86 13771996022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026